Royle Eenigenburg, MD
Psychiatry · Juneau, WINPI 1104858836
Payments from drug & device makers
Across 996 payments — averaging $345.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$130K
- E.r. Squibb & Sons, L.L.C.$70K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$60K
- Teva Pharmaceuticals USA, Inc.$52K
- Johnson & Johnson$13K
- AbbVie$9K
- plus $9K from 17 others
What the payments were for
- Consulting fees$34,83010%
- Speaking & faculty fees$263,52877%
- Travel & lodging$26,4048%
- Food & beverage$19,0156%
- Education$3630%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 231 | $129,769 |
| E.r. Squibb & Sons, L.L.C. | 95 | $70,481 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 97 | $60,085 |
| Teva Pharmaceuticals USA, Inc. | 87 | $51,755 |
| Johnson & Johnson | 70 | $13,151 |
| AbbVie(2 entities) | 99 | $9,433 |
| Indivior Inc. | 14 | $3,794 |
| Lundbeck LLC | 102 | $1,593 |
| Sunovion Pharmaceuticals Inc. | 15 | $978 |
| Otsuka America Pharmaceutical, Inc. | 61 | $801 |
| Vanda Pharmaceuticals Inc. | 20 | $427 |
| Supernus Pharmaceuticals, Inc. | 24 | $403 |
| Takeda Pharmaceuticals U.S.A., Inc. | 21 | $364 |
| Neurocrine Biosciences, Inc. | 18 | $294 |
| Idorsia Pharmaceuticals US Inc | 11 | $192 |
| Axsome Therapeutics, Inc. | 9 | $184 |
| Corium, LLC | 9 | $136 |
| Livanova USA, Inc. | 1 | $105 |
| Collegium Pharmaceutical, Inc. | 6 | $97 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 3 | $57 |
| Noven Therapeutics, LLC | 1 | $22 |
| Tris Pharma Inc | 1 | $16 |
| Janssen Scientific Affairs, LLC | 1 | $3 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$344,140 in reported general payments places this provider in the 95th percentile of 543 psychiatry providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 93 | $288,955 |
| VraylarCariprazine Hcl | 128 | $202,588 |
| Austedo XrDeutetrabenazine | 13 | $184,004 |
| LybalviOlanzapine/Samidorphan Malate | 112 | $173,159 |
| Abilify MaintenaAripiprazole | 56 | $148,479 |
| Invega TrinzaPaliperidone Palmitate | 21 | $115,318 |
| IngrezzaValbenazine Tosylate | 13 | $113,971 |
| TrintellixVortioxetine Hydrobromide | 202 | $97,665 |
| RexultiBrexpiprazole | 47 | $63,107 |
| CaplytaLumateperone Tosylate | 35 | $61,007 |
| QuviviqDaridorexant Hcl | 107 | $50,603 |
| AuvelityDextromethorphan Hbr/Bupropion | 48 | $44,774 |
| BelsomraSuvorexant | 55 | $23,978 |
| Paliperidone ErPaliperidone | 83 | $19,730 |
| FetzimaLevomilnacipran Hcl | 34 | $16,874 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Invega Trinza, Concerta | $13,151 | $413,128125 claims |
| AbbVieVraylar, Fetzima | $9,433 | $219,462162 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $801 | $211,586103 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Loxapine | $51,755 | $187,39282 claims |
| Alkermes, Inc.Lybalvi | $129,769 | $173,159112 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $294 | $113,97113 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $364 | $101,895213 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $60,085 | $61,00735 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $192 | $50,603107 claims |
| Axsome Therapeutics, Inc.Auvelity | $184 | $44,77448 claims |
| E.r. Squibb & Sons, L.L.C.Cobenfy | $70,481 | $16,29713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 543 psychiatry providers in Wisconsin.
Other psychiatry in Juneau
- Scott WienerGreenfield$1.4M
- Anne KoplinMadison$613K
- Joseph BergsRacine$346K
- Thomas IlicMilwaukee$324K
- Jay WinstonMilwaukee$238K
- Rise FuttererMadison$203K
- Joseph BurgarinoMilwaukee$111K
- Sobia Kirmani MoeMadison$104K
- Steven GarlowMadison$97K
- Jacob BehrensMilwaukee$94K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.